Startups
Protego Bio is a clinical-stage biotech developing first-in-class small molecule pharmacological chaperones for AL amyloidosis and other protein misfolding diseases.
Overview
Total raised
$130M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 25, 2025 | Droia Oncology Ventures | droiaventures.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 1, 2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| Dec 1, 2025 | Protego Biopharma Raises $130M in Series B Financing | Brent Warner, CEO of Protego Biopharma Protego Biopharma, Inc., a San Diego, CA-based clinical-stage biotechnology company, closed a $130m Series B financing. The round was led by Novartis Venture Fund and Forbion, with participation from n... |
Reviews 0
FAQ about Protego Bio
How much funding has Protego Bio raised?
Protego Bio has raised $130M in total across 1 funding round.
Who has invested in Protego Bio?
Parsers VC lists 2 investors of Protego Bio, among them Droia Oncology Ventures.
What has the press written about Protego Bio?
Parsers VC has collected 3 articles mentioning Protego Bio, among them “Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program” (Dec 1, 2025) and “Protego Biopharma Raises $130M in Series B Financing” (Dec 1, 2025).
Is Protego Bio still active?
Yes, Protego Bio is active; its latest activity on Parsers VC dates from Dec 25, 2025.